MYD88 L265P mutation status in small B-cell lymphoma with plasmacytic differentiation and extensive amyloid deposition
Keywords:
MYD88 L265P mutation, Waldenstrom macroglobulinemia, Small B-cell lymphoma, Plasmacytic differentiation, AmyloidAbstract
Background: MYD88 L265P mutation has been used to distinguish lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/WM) from marginal zone lymphoma (MZL) with plasmacytic differentiation (PCD). This determination is helpful when clinical findings cannot separate out these 2 entities. But the prevalence of MYD88 L265P mutation and its association with small B-cell lymphoma with PCD (SBCL-PCD) and extensive amyloid deposition, a rare condition, is not known.
Materials and Methods: Retrospective study of SBCL-PCD and extensive amyloid deposition was subject to detection for MYD88 L265P mutation.
Results: Total of 10 cases (5 each with systemic or localized disease) were included in the study. Only one case with systemic disease had MYD88 L265P mutation.
Conclusion: Most cases of SBCL-PCD and extensive amyloid deposition do not show MYD88 L265P mutation, suggestive of MZL with PCD over LPL/WM.
Downloads
References
Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJ, Sekijima Y, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2018;25(4):215-9.
Hawkins PN. Amyloidosis. Blood Rev. 1988;2:270-80.
Gertz MA. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment. Am J Hematol. 2018;93(9):1169-80.
Müller AM, Geibel A, Neumann HP, Kühnemund A, SchmittGräff A, Böhm J, et al. Primary (AL) Amyloidosis in Plasma Cell Disorders. Oncologist. 2006;11(7):824-30.
Telio D, Bailey D, Chen C, Crump M, Reece D, Kukreti V. Two distinct syndromes of lymphoma-associated AL amyloidosis: a case series and review of the literature. Am J Hematol. 2010;85(10):805-8.
Gono T, Matsuda M, Shimojima Y, Ishii W, Yamamoto K, Koyama J, et al. IgM AL amyloidosis due to B cell lymphoproliferative disorder: efficacy of high-dose melphalan followed by autologous stem cell transplantation. Amyloid. 2004;11(2):130-5.
Sanchorawala V, Blanchard E, Seldin DC, O’Hara C, Skinner M, Wright DG. AL amyloidosis associated with B-cell lymphoproliferative disorders: frequency and treatment outcomes. Am J Hematol. 2006;81(9):692-5.
Gertz MA, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström’s macroglobulinemia. J Clin Oncol. 1993;11(5):914-20.
Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Dispenzieri A, Muchtar E, et al. Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. Leukemia. 2019;33:790-4.
Palladini G, Merlini G. Diagnostic challenges of amyloidosis in Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013;13(2):244-6.
Thakral B, Kanagal-Shamanna R. Systemic AL amyloidosis associated with Waldenström macroglobulinemia: an unusual presenting complication. Blood. 2016;127(1):168.
Kourelis TV, Gertz M, Zent C, Lacy M, Kyle R, Kapoor P, et al. Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol. 2013;88(5):375-8.
Ikee R, Kobayashi S, Hemmi N, Suzuki S, Miura S. Amyloidosis associated with chronic lymphocytic leukemia. Amyloid. 2005;12:131-4.
Basset M, Defrancesco I, Milani P, Rattotti S, Foli A, Varettoni M, et al. Light Chain Amyloidosis and Non-Hodgkin’s Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome. Blood. 2018;132(Suppl 1):2026.
Ryan RJ, Sloan JM, Collins AB, Mansouri J, Raje NS, Zukerberg LR, Ferry JA. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue with amyloid deposition: a clinicopathologic case series. Am J Clin Pathol. 2012;137(1):51-64
Belfeki N, Bellefquih S, Bourgarit A. Breast MALT lymphoma and AL amyloidosis complicating Sjögren’s syndrome. BMJ Case Rep. 2019;12(4):e227581.
Upadhaya S, Baig M, Towfiq B, Al Hadidi S. Nodular pulmonary amyloidosis with primary pulmonary MALT lymphoma masquerading as metastatic lung disease. J Community Hosp Intern Med Perspect. 2017;7(3):185-9.
Swerdlow SH, Campo E, Harris L, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition. Lyon (France): IARC; 2017.
Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. Blood. 2013;121(13):2522-8.
Je EM, Yoo NJ, Lee SH. Absence of MYD88 gene mutation in acute leukemias and multiple myelomas. Eur J Haematol. 2012;88(3):273-4.
Ondrejka SL, Lin JJ, Warden DW, Durkin L, Cook JR, Hsi ED. MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders. Am J Clin Pathol. 2013;140(3):387-94.
Hamadeh F, MacNamara SP, Aguilera NS, Swerdlow SH, Cook JR. MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma. Mod Pathol. 2015;28(4):564-74.
Shin SY, Lee ST, Kim HY, Park CH, Kim HJ, Kim JW, et al. Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas. Blood Res. 2016;51(3):181-6.
Insuasti-Beltran G, Gale JM, Wilson CS, Foucar K, Czuchlewski DR. Significance of MYD88 L265P Mutation Status in the Subclassification of Low-Grade B-Cell Lymphoma/Leukemia. Arch Pathol Lab Med. 2015;139(8):1035-41.
Yu X, Li W, Deng Q, Li L, Hsi ED, Young KH, et al. MYD88 L265P mutation in lymphoid malignancies. Cancer Res. 2018;78(10):2457-62.
Chakraborty R, Novak AJ, Ansell SM, Muchtar E, Kapoor P, Hayman SR, et al. First report of MYD88 L265P somatic mutation in IgM-associated light-chain amyloidosis. Blood. 2016;127(23):2936-8.
Lim JK, Lacy MQ, Kurtin PJ, Gertz MA. Pulmonary marginal zone lymphoma of MALT type as a cause of localized pulmonary amyloidosis. J Clin Pathol. 2001;54(8):642-6.
Zhang HY, Liu AL, Zhou LS, He MX, Wang JX. Primary cutaneous marginal zone B-lymphoma with amyloid deposition: report of two cases with review of literature. Chin J Cancer. 2010;29(6):634-40.
He M, Wu L, Zhu M, Bai C, Zhang S, Wang J. Primary cutaneous MZL with amyloid deposition, initially misdiagnosed as amyloidosis mimics primary dural MZL upon dural dissemination. Op J Pathol. 2019;3(1):21-5.
Satani T, Yokose T, Kaburagi T, Asato Y, Itabashi M, Amemiya R. Amyloid deposition in pulmonary marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Pathol Int. 2007;57(11):746-50
Lehman NL, Horoupian DS, Wamke RA, Sundram UN, Peterson K, Harsh GR 4th. Dural marginal zone lymphoma with massive amyloid deposition: rare low grade primary central nervous system B-cell lymphoma case report. J Neurosurg. 2002;96(2):368-72.
Stuhlmann-Laeisz C, Schönland SO, Hegenbart U, Oschlies I, Baumgart JV, Krüger S, Röcken C. AL amyloidosis with a localized B cell neoplasia. Virchow Arch. 2019;474(3):353-63.
Sukpanichnant S. Analysis of 1983 cases of malignant lymphoma in Thailand according to the World Health Organization classification. Hum Pathol. 2004;35(2):224-30.
Intragumtornchai T, Bunworasate U, Wudhikarn K, Lekhakula A, Julamanee J, Chansung K, et al. Non-Hodgkin Lymphoma in South East Asia: An Analysis of the Histopathology, Clinical Features, and Survival From Thailand. Hematol Oncol. 2018;36(1):28-36.
